Today: 17 July 2026
LVMH share price drops to €609 as luxury stocks slide — investors brace for Jan. 22 results
17 January 2026
1 min read

LVMH share price drops to €609 as luxury stocks slide — investors brace for Jan. 22 results

Paris, Jan 17, 2026, 17:28 CET — The market has closed.

  • LVMH ended Friday trading at €609.20, slipping 2.6% amid the steepest drop seen in European luxury stocks in months.
  • Saks Global’s bankruptcy filing added strain on luxury brands tied to the U.S. department-store sector.
  • Next week, LVMH’s full-year results will draw attention for insights into China and the U.S. markets.

Shares of LVMH Moet Hennessy Louis Vuitton (LVMH.PA) closed Friday at 609.20 euros, slipping 2.64%. The luxury giant faces pressure ahead of a busy week for the sector.

Paris is closed for the weekend, leaving traders to decide if this selloff is just a quick dip or the beginning of a deeper slide. With LVMH’s earnings report nearly here, the stock’s price is shifting more on positioning bets than on fundamentals.

Luxury stocks weighed on European markets Friday, dragging the sector down while the broader STOXX 600 stayed flat. The luxury index dropped 3.2%, marking its worst day since early October. Richemont fell after BofA Global Research downgraded the stock, pointing to stretched valuations. “The margin of safety that investors had previously is gone,” said Morningstar strategist Michael Field. Reuters

Traders also flagged jitters in the U.S. department-store sector following Saks Global’s Chapter 11 bankruptcy filing this week, alongside its announcement of a $1.75 billion financing deal. JLL’s Matt Weko suggested a “sale-leaseback” — selling assets and leasing them back — as a possible cash-raising strategy. Reuters

The mood remains unsettled despite solid numbers. Cartier-owner Richemont reported Thursday an 11% sales increase at constant exchange rates — a figure that excludes currency fluctuations — beating expectations. Sales in China, Hong Kong, and Macau nudged up 2%, a sign RBC analyst Piral Dadhania described as “a pivotal moment” for the broader luxury market. Reuters

Investors in LVMH are keen to find out if the pickup in China is spreading beyond jewellery to the group’s main profit driver: fashion and leather goods. They’ll also be looking for clues on U.S. demand and discounting, especially as wholesale pressures resurface in the news.

Outside of trading, LVMH announced on Friday that Michèle Benbunan will take over as CEO of its Les Echos–Le Parisien media division starting Jan. 22. She will also manage the group’s other media properties.

None of this shifts the immediate momentum behind the shares. Monday’s open will reveal if buyers return after Friday’s drop or if the sector remains under pressure heading into earnings.

The setup works both ways. Should LVMH miss on guidance, or if the Saks fallout triggers broader doubts about wholesalers’ capacity to absorb inventory, luxury stocks might remain under pressure despite solid headline figures.

LVMH’s full-year results, due Jan. 22, stand out as the next major trigger for its stock. Investors will watch closely for any remarks on China and the U.S., which could influence rivals like Hermès and Kering.

Khadija Saeed is a financial markets reporter at TS2.tech, specializing in stocks, technology and emerging industries. She studied economics and finance at the London School of Economics and previously worked in market research before moving into financial journalism. Her coverage focuses on the companies, innovations and economic trends influencing global investors. Follow Khadija Saeed on Google News.

Stock Market Today

  • REGENXBIO sets $100 million public share and warrant offering
    July 17, 2026, 8:21 AM EDT. REGENXBIO Inc. (Nasdaq: RGNX) has announced the pricing of a public offering consisting of 10 million common shares at $9.00 per share and 1.1 million pre-funded warrants at approximately $9.00 each, targeting proceeds of about $100 million before deducting expenses. The deal is expected to close on July 20, 2026, pending standard closing conditions. Morgan Stanley, J.P. Morgan, Leerink Partners, and Mizuho serve as underwriters, with a 30-day option to purchase an additional 1.67 million shares. The transaction follows a filed SEC registration statement and is intended to fund further gene therapy work. Pre-funded warrants are often used in biotech financing, letting holders invest less upfront and convert to stock at a later date.
Semiconductor stocks rally as TSMC lifts 2026 capex to $56 billion; ASML hits $500 billion mark
Previous Story

Semiconductor stocks rally as TSMC lifts 2026 capex to $56 billion; ASML hits $500 billion mark

Singapore Airlines stock price: Air India pact in focus after C6L closes at S$6.35
Next Story

Singapore Airlines stock price: Air India pact in focus after C6L closes at S$6.35

Go toTop